Envestnet Asset Management Inc. Has $15.48 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Envestnet Asset Management Inc. trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 7.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 248,058 shares of the company’s stock after selling 20,285 shares during the period. Envestnet Asset Management Inc. owned about 0.50% of Prestige Consumer Healthcare worth $15,479,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare by 4.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after buying an additional 70,376 shares during the last quarter. Geode Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after purchasing an additional 9,455 shares during the last quarter. Westwood Holdings Group Inc. raised its position in shares of Prestige Consumer Healthcare by 2.4% in the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after purchasing an additional 20,626 shares during the period. Bank of America Corp DE lifted its stake in shares of Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after buying an additional 115,459 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Prestige Consumer Healthcare by 12.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company’s stock valued at $44,190,000 after buying an additional 63,168 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.2%

Shares of Prestige Consumer Healthcare stock opened at $66.81 on Monday. The company has a market capitalization of $3.16 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 2.10 and a beta of 0.43. The stock has a fifty day simple moving average of $63.81 and a 200 day simple moving average of $63.55. Prestige Consumer Healthcare Inc. has a 12-month low of $57.25 and a 12-month high of $90.04. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company’s quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter last year, the business posted $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PBH has been the subject of several research analyst reports. Jefferies Financial Group cut their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Finally, Oppenheimer lowered their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average target price of $80.60.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 2,000 shares of company stock valued at $125,930. 1.40% of the stock is owned by company insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).